Responsiveness to parenteral iron therapy in children with oral iron-refractory iron-deficiency anemia
Göster/ Aç
Erişim
info:eu-repo/semantics/embargoedAccessTarih
2014Yazar
Akın, MehmetAtay, Enver
Öztekin, Osman
Karadeniz, Cem
Karakus, Yasin Tuğrul
Yılmaz, Bilal
Erdoğan, Fırat
Üst veri
Tüm öğe kaydını gösterKünye
Akın, M., Atay, E., Öztekin, O., Karadeniz, C., Karakus, Y. T. Yılmaz, B. ... Erdoğan, F. (2014). Responsiveness to parenteral iron therapy in children with oral iron-refractory iron-deficiency anemia. Pediatric Hematology and Oncology, 31(1), 57-61. https://dx.doi.org/10.3109/08880018.2013.829540Özet
Intravenous (IV) ferric iron (Fe)-carbohydrate complexes are used for treating Fe deficiency in children with iron-refractory iron-deficiency anemia (IRIDA). An optimal treatment has yet to be determined. There are relatively little publications on the responsiveness to IV iron therapy in children with IRIDA. Patients and Method: This study analyzed responses to IV iron sucrose therapy given to 11 children, ranging in age from 2 to 13 years (mean 4.8 years), with iron-deficiency anemia who were unresponsive to oral iron therapy. Results: The hemoglobin and ferritin values (mean) of the 11 children with IRIDA were 7.7 g/dL and 4.8 ng/mL at diagnosis. Both hemoglobin and ferritin levels increased to 9.5 g/dL, and 24 ng/mL, respectively, at 6 weeks after the first therapy. Although the level of hemoglobin was steady at 6 months after the first, and 6 weeks after the second therapy, the ferritin levels continued to increase up to 30 ng/mL and 47 ng/mL at 6 months after the first and 6 weeks after the second therapy, respectively. Conclusion: We recommend that IRIDA should be considered in patients presenting with iron-deficiency anemia of unknown cause that is unresponsive to oral iron therapy. Our results suggest that IV iron therapy should be administered only once in cases of IRIDA. Continued administration of IV iron would be of no benefit to increase hemoglobin levels. On the contrary, ferritin levels may continue to increase resulting in untoward effects of hyperferritinemia.
WoS Q Kategorisi
Q3Scopus Q Kategorisi
Q2Kaynak
Pediatric Hematology and OncologyCilt
31Sayı
1Koleksiyonlar
- Makale Koleksiyonu [3651]
- PubMed İndeksli Yayınlar Koleksiyonu [4050]
- Scopus İndeksli Yayınlar Koleksiyonu [6286]
- WoS İndeksli Yayınlar Koleksiyonu [6433]